Trivalent inactivated influenza vaccine (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01436370 (ClinicalTrials.gov) | October 2011 | 15/9/2011 | TIV and High Dose TIV in Subjects With Rheumatoid Arthritis | A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels | Influenza | Biological: Trivalent inactivated influenza vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 18 Years | 64 Years | All | 102 | Phase 2 | United States |